On June 11, 2020, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Nyvepria™ (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegilgrastim). Nyvepria is indicated to decrease incidence of infection as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Read corporate press release.
Posted 6/12/2020
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
